Claris Biotherapeutics logo

Claris Biotherapeutics

Recent Financing

Series B

Recent Raise

$118M

Claris Biotherapeutics is a biotech developing CSB-001 (oremepermin alfa) eye drops to treat limbal stem cell deficiency and other front-of-eye diseases.

Founded 2018
New Jersey, United States
1-10
Private
clarisbio.com
PitchBook

Highlights

Focus Areas

Biotechnology
Health Care
Therapeutics

Recent Investors

Novo Holdings logo
Mass General Brigham Ventures logo
Janus Henderson Investors logo
Adage Capital Management logo
Sofinnova Ventures logo
Aisling Capital logo
ADAR1 Capital Management logo
Samsara BioCapital logo
Catalio Capital Management logo
RA Capital Management logo

Financials

$180.6M

Total Raised

4

Funding rounds

10

Investors

Team

Upgrade to view the team

See the team members at Claris Biotherapeutics.